Pharmas Add $42M in Merus’ Series B Extension Round
By Marie Powers
Wednesday, October 9, 2013
Merus BV enticed Johnson & Johnson Development Corp. (JJDC) to join existing investors Novartis Venture Fund and Pfizer Venture Investments for a big pharma trifecta in a €31 million (US$42 million) extension to its Series B financing.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.